New drugs for neglected diseases Descriptions are provided by the Actions directly via e-COST. The Action will pave the way for the development of novel drugs to treat neglected diseases such as African sleeping sickness, Chagas disease and Leishmaniasis. Related approaches of molecular genetics, biochemistry, medicinal chemistry, crystallography and bioinformatics will be coordinated and complemented with industrial experience. Established genomes are used to identify drug targets essential to the parasites but absent or different in the host, since inhibitors thereof hold promise as safe and efficacious therapeutics. Validated drug targets will serve as tools in drug discovery processes using complementary strategies: i) high-throughput screening of natural product and other compound libraries and ii) in silico screening of virtual libraries to identify novel leads; iii) chemical synthesis and optimization of identified leads; and iv) structure-based inhibitor design based on established structures or molecular models. The potential therapeutic profile of novel compounds active in vitro will be worked out by techniques of high prognostic value in respect to drug safety. The most promising compounds will be tested in established infection models for all the diseases to choose the most attractive candidates for preclinical and clinical development. The Action Actions are networks centred around nationally funded research projects in fields that are of i... members will cover all expertises required for the multidisciplinary early drug discovery phase. Keywords: Drug discovery, medicinal chemistry, African sleeping sickness, Chagas disease, Leishmaniasis Chemistry and Molecular Sciences and Technologies COST Action CM0801 Description Parties Management Committee CMST Icon General Information* Chair of the Action: Prof. Leopold FLOHE (DE) Vice Chair of the Action: Dr Theodora CALOGEROPOULOU (EL) Science officer of the Action: Dr Lucia FORZI Administrative officer of the Action: Ms Svetlana VOINOVA Downloads* Action Fact Sheet Download AFS as .RTF Memorandum of Understanding Download MoU as PDF Progress Report Download Progress Report as PDF Poster Download Poster as PDF Websites* Action website: http://www.costcm0801.org/CM0801/Welcome.html Domain website: http://www.cost.eu/cmst * content provided by e-COST. Data is synchronised once per night. Management Commette substitute for Italy- COST Action CM0801 List of all management Commette substitues-Country MC Substitute Greece Dr Anastasia DETSI Israel Prof. Joseph SHLOMAI Israel Prof. Hanoch SENDEROWITZ Italy Prof. Sergio ROMEO Italy Prof Maria Paola COSTI Portugal Dr Helena CASTRO Spain Dr Francisco GAMARRO Sweden Prof. Salam AL-KARADAGHI Switzerland Prof. Andreas MAYER United Kingdom Prof. Simon CROFT

Italian representative substitute of the COMMETTE MANAGEMENT for the COST CM1307 ANNI 2009-2013 / Costi, Maria Paola. - ELETTRONICO. - (2009), pp. 1-1.

Italian representative substitute of the COMMETTE MANAGEMENT for the COST CM1307 ANNI 2009-2013

COSTI, Maria Paola
2009

Abstract

New drugs for neglected diseases Descriptions are provided by the Actions directly via e-COST. The Action will pave the way for the development of novel drugs to treat neglected diseases such as African sleeping sickness, Chagas disease and Leishmaniasis. Related approaches of molecular genetics, biochemistry, medicinal chemistry, crystallography and bioinformatics will be coordinated and complemented with industrial experience. Established genomes are used to identify drug targets essential to the parasites but absent or different in the host, since inhibitors thereof hold promise as safe and efficacious therapeutics. Validated drug targets will serve as tools in drug discovery processes using complementary strategies: i) high-throughput screening of natural product and other compound libraries and ii) in silico screening of virtual libraries to identify novel leads; iii) chemical synthesis and optimization of identified leads; and iv) structure-based inhibitor design based on established structures or molecular models. The potential therapeutic profile of novel compounds active in vitro will be worked out by techniques of high prognostic value in respect to drug safety. The most promising compounds will be tested in established infection models for all the diseases to choose the most attractive candidates for preclinical and clinical development. The Action Actions are networks centred around nationally funded research projects in fields that are of i... members will cover all expertises required for the multidisciplinary early drug discovery phase. Keywords: Drug discovery, medicinal chemistry, African sleeping sickness, Chagas disease, Leishmaniasis Chemistry and Molecular Sciences and Technologies COST Action CM0801 Description Parties Management Committee CMST Icon General Information* Chair of the Action: Prof. Leopold FLOHE (DE) Vice Chair of the Action: Dr Theodora CALOGEROPOULOU (EL) Science officer of the Action: Dr Lucia FORZI Administrative officer of the Action: Ms Svetlana VOINOVA Downloads* Action Fact Sheet Download AFS as .RTF Memorandum of Understanding Download MoU as PDF Progress Report Download Progress Report as PDF Poster Download Poster as PDF Websites* Action website: http://www.costcm0801.org/CM0801/Welcome.html Domain website: http://www.cost.eu/cmst * content provided by e-COST. Data is synchronised once per night. Management Commette substitute for Italy- COST Action CM0801 List of all management Commette substitues-Country MC Substitute Greece Dr Anastasia DETSI Israel Prof. Joseph SHLOMAI Israel Prof. Hanoch SENDEROWITZ Italy Prof. Sergio ROMEO Italy Prof Maria Paola COSTI Portugal Dr Helena CASTRO Spain Dr Francisco GAMARRO Sweden Prof. Salam AL-KARADAGHI Switzerland Prof. Andreas MAYER United Kingdom Prof. Simon CROFT
Costi, Maria Paola
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1062011
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact